Stage-dependent BDNF serum concentrations in Alzheimer’s disease
First Online: 16 December 2005 Received: 01 June 2005 Accepted: 30 September 2005 DOI:
Cite this article as: Laske, C., Stransky, E., Leyhe, T. et al. J Neural Transm (2006) 113: 1217. doi:10.1007/s00702-005-0397-y Summary.
Alzheimer’s disease (AD) is characterized by cognitive decline and loss of neurons in specific brain regions. Recent findings have suggested an involvement of brain-derived neurotrophic factor (BDNF) in the pathogenesis of AD. BDNF is an endogenous protein involved in the maintenance of neuronal function, synaptic plasticity and structural integrity in the adult brain.
To our knowledge, the present pilot study assessed for the first time BDNF serum and CSF concentrations in 30 patients with different stages of AD in comparison to 10 age-matched non-demendet controls. AD patients were divided in two groups according to their MMSE score: Group 1 (n = 15) in early stages with MMSE scores ≥21 (mean of 25.5) and Group 2 (n = 15) with more severe stages of dementia with MMSE scores <21 (mean of 13.3).
As main results, we found in patients with early stages of probable AD significantly increased BDNF serum concentrations as compared to more severe stages of AD (p < 0.0001) and age-matched healthy controls (p = 0.028). BDNF serum values in all AD patients correlated significantly with MMSE scores (r = 0.486; p < 0.0001). Levels of BDNF were below the detection limit of the assay in unconcentrated CSF samples of AD patients and non-demendet controls.
In summary, BDNF serum values are increased in early stages of Alzheimer’s disease, which may reflect a compensatory repair mechanism in early neurodegeneration and could also contribute to increased degradation of beta-amyloid (Abeta). During the course of the disease, BDNF is decreasing, which correlates with the severity of dementia. The decrease of BDNF may constitute a lack of trophic support with an increase of Abeta accumulation and thus contribute to progressive degeneration of specific regions in the AD-affected brain. BDNF should be further evaluated as a candidate marker for clinical diagnosis and therapeutic monitoring in Alzheimer’s disease.
Keywords: Alzheimer’s disease (AD), early stages, late stages, BDNF, serum, CSF, healthy controls, MMSE. References Blasko, I, Grubeck-Loebenstein, B 2003 Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer’s disease Drugs Aging 20 101 113 PubMed CrossRef Brion, JP, Anderton, BH, Authelet, M, Dayanandan, R, Leroy, K, Lovestone, S, Octave, JN, Pradier, L, Touchet, N, Tremp, G 2001 Neurofibrillary tangles and tau phosphorylation Biochem Soc Symp 67 81 88 PubMed Burbach, GJ, Hellweg, R, Haas, CA, Del Turco, D, Deicke, U, Abramowski, D, Jucker, M, Staufenbiel, M, Deller, T 2004 Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice J Neurosci 24 2421 2430 PubMed CrossRef Connor, B, Young, D, Lawlor, P, Gai, W, Waldvogel, H, Faull, RL, Dragunow, M 1996 Trk receptor alterations in Alzheimer’s disease Brain Res Mol Brain Res 42 1 17 PubMed CrossRef APA 1994Diagnostic and statistical manual of mental disorders4 DSM-4. American Psychiatric Association Washington, DC Durany, N, Michel, T, Kurt, J, Cruz-Sanchez, FF, Cervas-Navarro, J, Riederer, P 2000 Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer’s disease brains Int J Dev Neurosci 18 807 813 CrossRef Folstein, MF, Folstein, SE, McHugh, PR 1975 “Mini-Mental-State”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189 198 PubMed CrossRef Foulstone, EJ, Tavare, JM, Gunn-Moore, FJ 1999 Sustained phosphorylation and activation of protein kinase B correlates with brain-derived neurotrophic factor and insulin stimulated survival of cerebellar granule cells Neurosci Lett 264 125 128 PubMed CrossRef Fujimura, H, Altar, CA, Chen, R, Nakamura, T, Nakahashi, T, Kambayashi, J, Sun, B, Tandon, NN 2002 Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation Thromb Haemost 87 728 734 PubMed Hock, C, Heese, K, Hulette, C, Rosenberg, C, Otten, U 2000 Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas Arch Neurol 57 846 851 PubMed CrossRef Holsinger, RM, Schnarr, J, Henry, P, Castelo, VT, Fahnestock, M 2000 Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease Brain Res Mol Brain Res 76 347 354 PubMed CrossRef Huang, EJ, Richardt, LF 2001 Neurotrophins: roles in neuronal development and function Annu Rev Neurosci 24 677 736 PubMed CrossRef Karege, F, Schwald, M, Cisse, M 2002 Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets Neurosci Lett 328 261 264 PubMed CrossRef Kerschensteiner, M, Gallmeier, E, Behrens, L, Leal, VV, Misgeld, T, Klinkert, WE, Kolbeck, R, Hoppe, E, Oropeza-Wekerle, RL, Bartke, I, Stadelmann, C, Lassmann, H, Wekerle, H, Hohlfeld, R 1999 Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation J Exp Med 189 865 870 PubMed CrossRef Kircher, T, Wormstall, H 1997 Alois Alzheimer (1864–1915) – student days and first scientific activities J Geriatr Psychiatry Neurol 10 127 129 PubMed Laske, C, Stransky, E, Eschweiler, G, Wittorf, A, Richartz-Salzburger, E, Bartels, M, Buchkremer, G, Schott, K 2005a BDNF serum concentrations in patients with Alzheimer’s disease are associated with depressive mood states Neurol Psychiatr Brain Res 12 1 4 Laske, C, Stransky, E, Eschweiler, GW, Wittorf, A, Richartz-Salzburger, E, Buchkremer, G, Schott, K 2005b Correlation of BDNF and IL-6 serum concentrations in Alzheimer’s disease Neurol Psychiatr Brain Res 12 21 24 Laske, C, Morawetz, C, Buchkremer, G, Wormstall, H 2005c Prevention of dementia Dtsch Ärztebl 102 A1446 1453
Laske C, Eschweiler GW (2006) Brain-derived neurotrophic factor (BDNF): from nerve growth factor to modulator of brain plasticity in cognitive processes and psychiatric diseases. Nervenarzt (in press)
Lindvall, O, Ernfors, P, Bengzon, J, Kokaia, Z, Smith, ML, Siesjo, BK, Persson, H 1992 Differential regulation of mRNAs for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the adult rat brain following cerebral ischemia and hypoglycemic coma Proc Natl Acad Sci USA 89 648 652 PubMed CrossRef Marmigere, F, Choby, C, Rage, F, Richard, S, Tapia-Arancibia, L 2001 Rapid stimulatory effects of brain-derived neurotrophic factor and neurotrophin-3 on somatostatin release and intracellular calcium rise in primary hypothalamic cell cultures Neuroendocrinology 74 43 54 PubMed CrossRef Mattson, MP, Maudsley, S, Martin, B 2004 BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders Trends Neurosci 27 589 594 PubMed CrossRef Mc Khann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM 1984 Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease Neurology 34 30 44 Meda, L, Cassatella, MA, Szendrei, GI, Otvos, L, Baron, P, Villalba, M, Ferrari, D, Rossi, F 1995 Activation of microglial cells by beta-amyloid protein and interferon-gamma Nature 374 647 651 PubMed CrossRef Michalski, B, Fahnestock, M 2003 Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease Brain Res Mol Brain Res 111 148 154 PubMed CrossRef Pan, W, Banks, WA, Fasold, MB, Bluth, J, Kastin, AJ 1998 Transport of brain-derived neurotrophic factor across the blood-brain barrier Neuropharmacology 37 1553 1561 PubMed CrossRef Phillips, HS, Hains, JM, Armanini, M, Laramee, GR, Johnson, SA, Winslow, JW 1991 BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease Neuron 7 695 702 PubMed CrossRef Poduslo, JF, Curran, GL 1996 Permeability at the blood-brain barrier and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF Mol Brain Res 36 280 286 PubMed CrossRef Saito, T, Iwata, N, Tsubuki, S, Takaki, Y, Takano, J, Huang, SM, Suemoto, T, Higuchi, M, Saido, TC 2005 Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation Nat Med 11 434 439 PubMed CrossRef Tang, Y, Yamada, K, Kanou, Y, Miyazaki, T, Xiong, X, Kambe, F, Murata, Y, Seo, H, Nabeshima, T 2000 Spatiotemporal expression of BDNF in the hippocampus induced by the continuous intracerebroventricular infusion of beta-amyloid in rats Brain Res Mol Brain 80 188 197 CrossRef Tong, L, Balazs, R, Thornton, PL, Cotman, CW 2004 Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons J Neurosci 24 6799 6809 PubMed CrossRef Villuendas, G, Sanchez-Franco, F, Palacios, N, Fernandez, M, Cacicedo, L 2001 Involvement of VIP on BDNF-induced somatostatin gene expression in cultured fetal rat cerebral cortical cells Brain Res Mol Brain Res 94 59 66 PubMed CrossRef
World Health Organization (WHO) (1988) Tenth revision of the International Classification of Diseases, chapter 5 (F). Mental and behavioural disorders (including disorders of psychological development). Clinical descriptions and diagnostic guidelines. WHO, Geneva
Yasutake, C, Yanagawa, T, Okamura, T, Yoneda, H 2005 Serum BDNF, TNF-alpha, IL-1beta levels in dementia patients World J Biol Psychiatry 6 215